In the NCCN Guidelines® Version 1.2022, it is stated that there are not sufficient data so far to suggest preventive management of breast cancer in carriers of GPVs of RAD51C or RAD51D (RAD51C/D). This evidence concerns the gene RAD51D and breast carcinoma.